Background This registrational trial evaluated the efficacy, safety, and patient-reported outcomes of axitinib versus sorafenib like a second-line treatment in Asian patients with clear-cell metastatic renal cell carcinoma (mRCC). 0.506C1.058; one-sided em P /em =0.0531). The target response price (95% CI) was 23.7% (16.8%C31.8%) with axitinib versus 10.1% (4.2%C19.8%) with sorafenib. Common, quality 3, all-causality… Continue reading Background This registrational trial evaluated the efficacy, safety, and patient-reported outcomes